Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Perspective: tumour spread--the problems of latency.

I R Hart1

  • 1Richard Dimbleby Department of Cancer Research/Imperial Cancer Research Fund, Rayne Institute, St Thomas' Hospital, London, U.K. i.hart@icrf.icnet.uk

The Journal of Pathology
|May 26, 1999
PubMed
Summary

Tumour dormancy, a state of cancer stasis, offers novel therapeutic potential. Strategies targeting tumour blood vessel formation (neovascularization) using anti-angiogenic peptides are nearing clinical application.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

BEME Guide No. 1: Best Evidence Medical Education.

Medical teacher·2011
Same author

Psoriasin (S100A7) associates with integrin β6 subunit and is required for αvβ6-dependent carcinoma cell invasion.

Oncogene·2010
Same author

Ezrin interacts with cortactin to form podosomal rosettes in pancreatic cancer cells.

Gut·2008
Same author

Colocalization of kindlin-1, kindlin-2, and migfilin at keratinocyte focal adhesion and relevance to the pathophysiology of Kindler syndrome.

The Journal of investigative dermatology·2008
Same author

Early onset of breast cancer in a group of British black women.

British journal of cancer·2008
Same author

Development of a quantitative method to analyse tumour cell invasion in organotypic culture.

The Journal of pathology·2005

Area of Science:

  • Oncology
  • Vascular Biology
  • Cancer Therapeutics

Background:

  • Tumour latency, or dormancy, is a recognized clinical phenomenon in neoplastic disease.
  • Understanding dormancy mechanisms is crucial for developing novel therapeutic strategies.
  • Neovascularization and the balance of angiogenic/anti-angiogenic peptides are key factors in tumour dormancy.

Purpose of the Study:

  • To explore tumour dormancy as a therapeutic target.
  • To investigate the role of neovascularization in maintaining tumour latency.
  • To evaluate the potential of anti-angiogenic peptides in controlling tumour growth.

Main Methods:

  • Review of current literature on tumour dormancy.
  • Analysis of the role of neovascularization in tumour latency.

Related Experiment Videos

  • Assessment of angiogenic and anti-angiogenic peptide balance.

    • Main Results:

    • Tumour dormancy represents a viable state for therapeutic intervention.
    • Shifts in angiogenic and anti-angiogenic peptide balance influence tumour dormancy.
    • Targeting tumour vasculature is a promising approach.

    Conclusions:

    • Inducing or maintaining tumour dormancy offers a novel therapeutic avenue.
    • Modulating neovascularization through anti-angiogenic peptides is a promising strategy.
    • Clinical evaluation of anti-angiogenic peptide-based therapies is imminent.